Çàðåãèñòðèðîâàòüñÿ

Ïîõîæèå òåìû

  1. "Çîëîòîé øåëê" è äðóãàÿ êîñìåòèêà "Íàðîäíûå ïðîìûñëû"
    îò QzQ â ðàçäåëå Êîñìåòîëîãèÿ è êðàñîòà
    Îòâåòîâ: 8
    : 27.09.2013, 09:14
  2. Ïî÷åìó áû ìóæèêàì íà âîïðîñ "×òî äåëàåøü?" íå îòâåòèòü "Äóìàþ î òåáå!"
    îò imported_ÌÏ â ðàçäåëå Ñåêñ è ñåêñîïàòîëîãèÿ, îòíîøåíèÿ.
    Îòâåòîâ: 35
    : 23.11.2011, 02:56
  3. Îòâåòîâ: 0
    : 16.07.2007, 20:28
  4. Âîïðîñû ïî "ãîðìîíîïîäîáíîìó äåéñòâèþ" íåêîòîðûõ âåùåñòâ
    îò Ëåëèê â ðàçäåëå Ãèíåêîëîã-àêóøåð, áåðåìåííîñòü, ðîäû
    Îòâåòîâ: 9
    : 01.09.2004, 20:30
  5. Ïðàâèëà Êîíñóëüòàöèé (èëè "Êàê çàäàâàòü âîïðîñû")
    îò AlexK â ðàçäåëå Îíêîëîãè÷åñêèå çàáîëåâàíèÿ, ðàê
    Îòâåòîâ: 5
    : 01.09.2004, 20:30
  1. Ëåëèê
    #1
    ×èòàòåëü Íåäóã.Ðó
    Íåäàâíî íàòîëêíóëñÿ íà ñòàòüþ, ïðåòåíäóþùóþ íà íàó÷íóþ. Öèòàòà: "Ê ôèòîýñòðîãåíàì îòíîñÿòñÿ ñòåðèíû, ôëàâîíû, ôëàâîíîèäû, èçîôëàâîíîèäû, êóìåñòàíû, ëèãíàíû è õàëêîíû. Ïîìèìî ýñòðîãåíîïîäîáíîãî äåéñòâèÿ, ôèòîýñòðîãåíû ïðîÿâëÿþò......".





    Åùå öèòàòà: "Ñîÿ ñîäåðæèò èçîôëàâîíû ãåíèñòåèí è äàéäçåèí. Ãåíèñòåèí è äàéäçåèí ìîãóò ïðèñóòñòâîâàòü â ðàñòåíèÿõ â âèäå àãëèêîíîâ èëè ãëèêîçèäîâ.  êèøå÷íèêå ãëèêîçèäû ãèäðîëèçóþòñÿ ïîä äåéñòâèåì êèøå÷íîé ìèêðîôëîðû è ïðåâðàùàþòñÿ â àãëèêîíû äàéäçåèí è ãåíèñòåèí, äàéäçåèí â äàëüíåéøåì ÷àñòè÷íî òðàíñôîðìèðóåòñÿ â ýêâîë. Êàê âûÿñíèëîñü, ãëèêîçèäû èçîôëàâîíîâ ñïîñîáíû âûçâàòü ýñòðîãåííûé îòâåò êëåòîê. Íåìíîãî âûøå ýñòðîãåííàÿ àêòèâíîñòü ó àãëèêîíîâ ãåíèñòåèíà è äàéäçåèíà. Îäíàêî ñàìûé ñóùåñòâåííûé âêëàä â ýñòðîãåííîå äåéñòâèå ñîè âíîñèò ýêâîë, êîòîðûé ïî ñâîåé ñòðóêòóðå áîëüøå âñåãî íàïîìèíàåò ýñòðàäèîë. "







    Âîïðîñû:

    1. Âñòðå÷àëèñü ëè Âû ñ òàêîé èíôîðìàöèåé â áîëåå íàó÷íûõ èñòî÷íèêàõ?

    2. Íàñêîëüêî ïðàâîìåðíî ãîâîðèòü î ýñòðîãåíîïîäîáíîì äåéñòâèè òåõ âåùåñòâ, êîòîðûå íå ÿâëÿþòñÿ ãîðìîíàìè?  ÷àñòíîñòè ìåíÿ èíòåðåñóþò èìåííî ôëàâîíîèäû.

    3. Êàêèì îáðàçîì äîëæåí áûòü âûäåðæàí äèçàéí èññëåäîâàíèé, äëÿ äîêàçàòåëüñòâà ýñòðîãåíîïîäîáíîãî äåéñòâèÿ êàêèõ áû òî íè áûëî âåùåñòâ?

  2. shura_zd
    #2
    ×èòàòåëü Íåäóã.Ðó
    Âèòàëèé , ôèòîñòåðîèäû àáñîëþòíî çàêîííûé òåðìèí , è Âû ñàìè ýòî çíàåòå ñî âðåìåí èíñòèòóòà - ñòåðîèäíàÿ ñòðóêòóðà ãëèêîçèäîâ è ÿâèëàñü îñíîâîé èõ êàðäèîòðîïíîãî ýôôåêòà ( îäíî âðåìÿ âñåðüåç ãîâîðèëîñü î ìåõàíèçìàõ äåéñòâèÿ , îáóñëîâëåííûõ ñõîäñòâîì ÄÝAÑ è ãëèêîçèäîâ, î÷åíü àêòèâíî âåäóòñÿ ðàñøèôðîâêè âçàèìîäåéñòâèÿ òîãî æå æåíüøåíÿ ñ ðàçëè÷íûìè ýñòðîãåíîâûìè ðåöåïòîðàìè ) .

    Íó âîò êîìó èç íàñ ïðèäåò â ãîëîâó ñïðîñèòü æåíùèíó ñ äèñôóíêöèîíàëüíûìè ìàòî÷íûìè êðîâîòå÷åíèÿìè íå ïîëüçóåòñÿ ëè îíà " äëÿ óêðåïëåíèÿ çäîðîâüÿ " æåíüøåíåì? À âåäü â ðàçíûõ êîíöåíòàðöèÿõ, íà ðàçíûõ ïëàíòàöèÿõ , â ðàçíûõ âîçðàñòíûõ ãðóïïàõ è ïð. è äð.

    Ïîñêîëüêó ýôôåêòû ðàñòèòåëüíûõ ïðåïàðàòîâ íèêîãäà íå ôèêñèðóþòñÿ êàê ïîáî÷íûå , âðà÷è è íàðîä óáåæäåíû â òîì , ÷òî ó ïðåïàðàòîâ èç ðàñòèòåëüíîãî ñûðüÿ êàê áû è íåò õèìè÷åñêîé ñòðóêòóðû .

    Òà æå ñîÿ ñèìïàòè÷íà êàê ôÈÒÎÝÑÒÐÎÃÅÍ ( â íàøåé ñòðàíå ìíîãî ðàáîòàåò Áåðøòåéí âÑÏÁ , åãî ñòàòüè åñòü â Ïðîáëåìàõ ýíäîêðèíîëîãèè ) , íî ïðîáëåìàòè÷íà êàê çîáîãåí . Ò.å , êàê ïèøóò èññëåäîâàòåëè ( à ðàáîò ìèëëèàðä - ïðîáëåìà îñòàåòñÿ âî ìíîãîì íåÿñíîé , íî îòêðûâàþòñÿ íîâûå ïóòè äëÿ èçó÷åíèÿ ñåëåêòèâíûõ ìîäóëÿòîðîâ ñòåðîèäíûõ ðåöåïòîðîâ ) .

     íàñòîÿùåå âðåìÿ ÷åòêî ïîäòâåðæäàííîé â ìíîãîöåíòðîâûõ êëèíè÷åñêèõ èññëåäîâàíèÿõ äîêàçàííîé ýôôåêòèâíîñòè ïðåïàðàòîâ ñîè èëè åå äëèòåëüíîãî íàçíà÷åíèÿ íåò , íî ýïèäåìèîëîãè÷åñêèå èññëåäîâàíèÿ ïîä÷åðêèâàþò íèçêóþ ÷àñòîòó âåãåòàòèâíûõ ïðîÿâëåíèé êëèìàêòåðè÷åñêîãî ñèíäðîìà ó àçèàòîê . Ôèòîýñòðîãåíû â ïèùå - îäíî èç îáúÿñíåíèé , ãåíåòè÷åñêèå è êóëüòóðàëüíûå îñîáåííîñòè -äðóãîå .

    Íî óæ íàðêîëîãó -òî êàê óäèâëÿòüñÿ íàëè÷èþ õèìè÷åñêèõ ëèãàíäîâ â òðàâêàõ - ìàðèõóàíà , ýôåäðà è êîíîïëÿ âûðîñëè èç Çåìëè , êàê ãîâàðèâàë Ôèëàòîâ - "÷àé , íå õèìèÿ êàêàÿ , ÷àé , ïðèðîäíàÿ ñðåäà ".

  3. Alex1982d
    #3
    ×èòàòåëü Íåäóã.Ðó
    ß íå ïðî âîïðîñû ñòåðîèäíûõ ãëèêîçèäîâ.



    Ôëàâîíîèäû ÍÈÊÀÊÎÃÎ îòíîøåíèÿ ê ñòåðîèäàì íå èìåþò. Õîòÿ è îáðàçóþò â ðàñòåíèÿõ ñâÿçè ñ ñàõàðàìè, íàçûâàåìûå òàê æå ãëèêîçèäàìè. Íî ñòåðîèäíûå ãëèêîçèäû è ôëàâîíîèäíûå - äâå îãðîìíûå ðàçíèöû. Ìîëåêóëó êàêîãî-ëèáî ñàõàðà ìîæíî è ê áåíçîëó ïðèöåïèòü, è ê ñïèðòó, ÷åðåç -î- ñâÿçè, îò ýòîãî îí áóäåò íàçûâàòüñÿ ãëèêîçèäîì, íî íèêàê íå ñòåðîèäîì è ñòðàííî áûëî áû ïðåòåíäîâàòü íà ãîðìîíîïîäîáíîå äåéñòâèå.

    À æåíøåíü, êîòîðûé Âû óïîìèíàåòå, èìååò ñàïîíèíû äàììàðàíîâîãî ðÿäà, òå äà - õîòü ÷åì-òî ïîõîæè ïî õèìè÷åñêîé ñòðóêòóðå íà ñòåðîèäû.





    Ìîæíî ëè Âàñ ïîïðîñèòü õîòÿ áû êðàòêî ðàññêàçàòü ìíå ïî âîïðîñó 3. Êàêîé äîëæåí áûòü äèçàéí èññëåäîâàíèé äëÿ îáîñíîâàíèÿ ýñòðîãåíîïîäîáíîãî äåéñòâèÿ òîãî, ÷òî äàæå ïî õèìñòðóêòóðå è áëèçêî íå îòíîñèòñÿ ê ñòåðîèäàì?

  4. ËàðèñàÊàðòàøîâà
    #4
    ×èòàòåëü Íåäóã.Ðó
    Âèòàëèé , ïðîáåæàëà ãëàçàìè ïðèâåäåííóþ ÂÀìè ññûëêó , è , ïîñêîëüó îíà îñîáî íà ìîçãè íå ëåãëà , ñòàëà ãîâîðèòü î òîì , ÷òî ìíå ñàìîé íàèáîëåå èíòåðåñíî â ýòîì ñåãìåíòå - âèíîâàòà .

    Åñëè ãîâîðèòü î äèçàéíå , òî âñå , ÷òî ìíå âñòðå÷àëîñü--ýòî óñòàíîâëåíèå õèìè÷åñêîé ñòðóêòóðû àëêàëîèäà , ìåòêà è èçó÷åíèå ñâÿçûâàíèÿ â ðåöåïòîðàìè + ìèëëèîí ðàáîò ñîáñòâåííî ïî ñòðóêòóðå ðåöåïòîðîâ .

    Ñ ôëàâîíîèäàìè ñëàáà , íî ÿ ïîìíþ , êàê äåñÿòîê ëåò íàçàä îñòåîïðîòåêòèâíûé ýôôåêò îñòåîõèíà Sanofi îáñóæäàëñÿ èìåííî â ñâÿçè ñî ñòðóêòóðíûìè ñõîäñòâîì ñî ñòåðîèäàìè - âî âñÿêîì ñëó÷àå , ïðåäïîëàãàëîñü\ îòâåðãàëîñü ñâÿçûâàíèå ñî ñòåðîèäíûìè ðåöåïòîðàìè . Ïîñêîëüêó ïðåïàðàò äàâíî âûòåñíåí áîëåå îò÷åòëèâî äåéñòâóþùèìè , ïîñìîòðþ , ÷òî åñòü åùå .

  5. Ñíåæàííà
    #5
    ×èòàòåëü Íåäóã.Ðó
    Ïåðâàÿ ïîïàâøàÿñÿ ññûëêà èç Pubmed - è òàì èõ íàâàëîì.

    Acta Physiol Hung 2002;89(4):463-70 Related Articles, Links





    Effect of single neonatal treatment with the soy bean phytosteroid, genistein on the sexual behavior of adult rats.



    Csaba G, Karabelyos C.



    Department of Genetics, Cell and Immunobiology, Semmelweis University, Budapest, Hungary.



    Hormonal imprinting develops during the perinatal critical period, when the target hormone meets the yet unmatured receptor. As a consequence of imprinting the receptor accomplishes its maturation reaching the binding capacity characteristic to adults. In this period in the presence of foreign molecules similar to the target hormone faulty imprinting may occur with life-long consequences. Soy bean contains phytosteroids which can mimic estrogen effects. In the present experiments single genistein (20 microg) or combined genistein + benzpyrene (20 microg) treatments were done neonatally and the sexual behavior of male and female adult animals was studied. Genistein significantly increased the lordosis quotient of females, which was compensated by neonatal benzpyrene treatment. Genistein also enhanced the sexual activity of males, and this was significantly not reduced by parallel benzpyrene treatment. The results show that neonatal genistein exposure can imprint sexual activity for life and the presence of a second imprinter can modify genistein's behavioral effect.



    PMID: 12489755 [PubMed - in process]



    --------------------------------------------------------------------------------

  6. Íàòàëè-Âèêòîðèÿ
    #6
    ×èòàòåëü Íåäóã.Ðó
    Ñòîëü æå ñëó÷àéíî ïîïàâøàÿñÿ äîñòàòî÷íî òèïè÷íàÿ ïóáëèêàöèÿ -

    : Eur J Cancer Prev 2003 Apr;12(2):165-9 Related Articles, Links





    Mammographic densities in a one-year isoflavone intervention.



    Maskarinec G, Williams AE, Carlin L.



    The estrogenic and antiestrogenic effects of isoflavones, phytoestrogens contained in soy foods, have been proposed as mechanisms for the possible involvement of soy products in the development of breast cancer. We investigated the hypothesis that isoflavones reduce mammographic density, a predictor of breast cancer risk. We conducted a double-blind randomized trial in premenopausal women who received a daily 100 mg isoflavone supplement or a placebo over 12 months. Compliance with the study regimen was confirmed by urinary isoflavones and tablet counts. We used a computer-assisted method to measure mammographic density and paired t-tests to assess changes in mammographic characteristics from baseline to follow-up mammogram. Complete sets of mammograms were available for 30 women. The two groups differed by age and mammographic density at baseline, but were similar in body weight and nutritional intakes. We detected no significant changes either in the size of the dense areas or in the per cent densities. A non-significant decrease in breast area among intervention group subjects was probably the result of methodological issues in comparing mammograms taken under different conditions. In conclusion, our findings do not support the hypothesis that isoflavones decrease mammographic density during a one-year intervention. Although this exploratory study had limited power, it appears that isoflavones do not exert an estrogenic effect similar to hormone replacement therapy on mammographic density.



    PMID: 12671541 [PubMed - in process]

  7. kmp
    #7
    ×èòàòåëü Íåäóã.Ðó
     òîì-òî è äåëî, ÷òî íà êàæäûé ðåïîðò î "ïëîõèõ" ýôôåêòàõ ìîæíî íàéòè ðåïîðò î "õîðîøèõ" ýôôåêòàõ. Ê òîìó æå, èññëåäîâàíèÿ ïðîâîäÿòñÿ â îñíîâíîì íà æèâîòíûõ èëè íà êëåòî÷íûõ êóëüòóðàõ, ïðè÷åì èñïîëüçóþòñÿ "óáîéíûå" êîíöåíòðàöèè. Êàê ñêàçàíî â îäíîé èç ñòàòåé: Steady state plasma concentrations of flavonoids are usually not much higher than 1 microM even in populations that consume large amounts of plant material. This concentration is relatively low compared to the concentrations of flavonoids that were commonly used in cell culture systems to demonstrate their effectiveness.







    Êîðî÷å, âñå ýòî îáëàñòü õîòü è íàó÷íîé, íî åùå ôàíòàñòèêè

  8. LUCKY
    #8
    ×èòàòåëü Íåäóã.Ðó
    Äîñòàòî÷íî òèïè÷íûé îáçîð , ïîääåðæèâàþùèé â öåëîì Âàøó òî÷êó çðåíèÿ , Âèòàëèé

    : J Steroid Biochem Mol Biol 2002 Dec;83(1-5):133-47 Related Articles, Links





    Phytoestrogens for hormone replacement therapy?



    Wuttke W, Jarry H, Westphalen S, Christoffel V, Seidlova-Wuttke D.



    Department of Clinical and Experimental Endocrinology, University of Goettingen, Robert-Koch-Strasse 40, 37075, Goettingen, Germany



    Due to some severe side effects "classical" hormone replacement therapy (HRT) is currently being challenged by a therapy with phytoestrogens. Particularly soy and red clover derived isoflavones are advertised as selective estrogen receptor modulators (SERMs) with only desired and no undesired estrogenic effects. Evidence that this is the case however is scarce. Most studies investigating climacteric complaints did not find beneficial effects. A proposed beneficial effect on mammary cancer is unproven. The majority of studies however indicate an antiosteoporotic effect of isoflavones, while putative beneficial effects in the cardiovascular system are questionable due to the fact that estradiol which-like isoflavones-increase HDL and decrease LDL concentrations appear not to prevent arteriosclerosis in the human. In the urogenital tract, including the vagina, soy and red clover derived isoflavones are without effects.Cimicifuga racemosa extracts are traditionally used for the treatment of climacteric complaints. Evidence is now available that the yet unknown compounds in Cimicifuga racemosa extracts prevent climacteric complaints and may also have antiosteoporotic effects.

  9. trollebus
    #9
    ×èòàòåëü Íåäóã.Ðó
    Ïðè ñðàâíåíèè ãîðìîíàëüíîé àêòèâíîñòè ýêñòð. êëåâåðà, ñîè ñ òî÷êè çðåíèÿ ñâÿçûâàíèÿ ðåöåïòîðîâ, èõ èçîôëàâîíû ìîæíî ðàññìàòðèâàòü êàê ñëàáûå ýñòðîãåíû, ïðîãåñòèíû èëè àíäðîãåíû (èõ àôôèííîñòü â äåñÿòêè-ñîòíè òûñÿ÷ ðàç íèæå íàòóð. ñòðîèäí. êîìïîíåíòîâ). Íûíåøíÿÿ ìåòîäîëîãèÿ íå ïîçâîëÿåò ðàçëè÷èòü àãîíèçì èëè àíòàãîíèçì ýòèõ âçàèìîäåéñòâèé. Ýêñòð. èç Cimicifuga racemosa âîîáùå íå îáëàäàåò òàêîâîé àêòèâíîñòüþ,

    J Steroid Biochem Mol Biol 2003 Feb;84(2-3):259-68

    Comparison of hormonal activity (estrogen, androgen and progestin) of standardized plant extracts for large scale use in hormone replacement therapy.

    Beck V, Unterrieder E, Krenn L, Kubelka W, Jungbauer A.

    Institute of Applied Microbiology, University of Natural Resources and Applied Life Sciences, Muthgasse 18, 1190, Vienna, Austria



    íî èìåííî åå ýêñòðàêò ïîêàçàë êàê íàèáîëåå ïðèåìëåìàÿ çàìåíà ÇÃÒ (åé ïîñâÿùåí âåñü Maturitas 2003 Mar 14;44 Suppl 1).

    Âêðàòöå â îðèãèíàëå:

    it was the first time that the therapeutic effects of an aqueous/ethanolic extract, C. racemosa BNO 1055 (Klimadynon®/ Menofem®), were investigated in a randomized three-armed, double-blind, and GCP-conform clinical trial. The comparison included a placebo and a positive control in the form of CE. The results clearly indicate that CR BNO 1055 has desired SERM activities, not only in the rat but also in postmenopausal women. While CE significantly increased endometrial thickness of the postmenopausal women, such effect was not seen in the CR BNO 1055 treated patients. It was repeatedly shown in the past that CR extracts do not stimulate uterine weight and the expression of estrogen-regulated uterine genes and their protein products. 17-Estradiol increased these parameters. Hence, it appears safe to conclude that the substance(s) with SERM activity present in CR BNO 1055 do not address the uterus. It is, therefore, unlikely that they may stimulate the endometrium to such an extent that an endometrial cancer may develop. Consequently, a treatment with CR BNO 1055 can be performed without additional progestin application.

    In the vagina, estrogens exert desired effects by stimulating acidity of the vaginal milieu. A lower pH prevents ascending infections. The increased number of superficial cells in the vaginal smears of patients treated with CE is a clear sign for estrogenic effects in the vagina. In comparison to placebo, vaginal superficial cells were also increased under CR BNO 1055 and this effect approached significance. Not only lowering of the vaginal pH but also lubrication upon sexual arousal is a desired estrogenic effect. Hence, CR BNO 1055 may fulfill in part also these desired criteria by exerting a mild estrogenic effect in the vagina of postmenopausal women.

    In a previous placebo-controlled study, using a higher than recommended CR doses [25] as well as in the present investigation, climacteric complaints were significantly reduced by treatment with placebo preparations. In addition to this placebo effect, both, CR BNO 1055 and the CE, had in the present study favorable and significant effects on climacteric complaints. We utilized the MRS [22] to estimate the effects of the treatment on climacteric complaints. Additionally, we followed the proposal to subcategorize the 10 MRS items into three factors [23]. The factor 1 "hot flushes" comprises the MRS item 1 "hot flushes", item 2 "cardiac symptoms", and item 3 "sleep disorders". This factor was obviously reduced by placebo and a significant improvement was noted under CE. CR BNO 1055 also showed an improvement, which, however, was not statistically significant. The factor 2 "psyche" comprises the MRS item 4 "depressive mood", item 5 "nervousness"/"irritability" and item 6 "impaired performance/memory". Factor 2 was obviously improved by placebo. A stronger improvement, though statistically not significant, was observed under CR BNO 1055 and CE. The factor 3 "atrophy" comprises the MRS item 7 "disorders of sexuality", item 8 "urinary symptoms", item 9 "vaginal dryness", and item 10 "joint and muscle symptoms". This factor was least improved under placebo, but significantly improved under CR BNO 1055 and CE.

    This study showed that treatment with placebo reduces the intensity of climacteric complaints. Particularly, susceptive to this placebo effect is the factor 1 "hot flushes". Less susceptive is the factor 2 "psyche" and least susceptive is the factor 3 "atrophy". The data also demonstrate that both, CE as well as CR BNO 1055, improved the three MRS factors in addition to a placebo effect. Analysis of the total MRS Score showed that CR BNO 1055 was as effective as CE in reducing climacteric complaints, when compared with placebo.

    The effects of CR BNO 1055 on neurovegetative symptoms are undoubtedly exerted in the brain. Items like hot flushes and tachycardiac episodes emerge due to an overactivation of the hypothalamic GnRH pulse generator, in consequence to a deficiency of estrogens [26]. In human, the overactivation was shown by a simultaneous occurrence of hot flushes and LH pulses in the serum. This effect is exerted by hypothalamic mechanisms, a structure where the GnRH pulse generator resides in. Investigations with rats repeatedly showed a reduction of LH pulsatility under aqueous/ethanolic C. racemosa extract BNO 1055. These data add to the evidence that the C. racemosa extract BNO 1055 contains yet unidentified compounds with an estrogenic effect on the hypothalamic GnRH pulse generator.

    The other climacteric complaints, particularly those subsumed under factor 2 "psyche", are certainly estrogenic effects in suprahypothalamic brain structures. Most likely they are exerted in the mesolimbic systems, which express ER and ER genes. Factor 3 "atrophy" is a somatic factor and comprises vaginal dryness and rheumatic-like complaints. Vaginal dryness is clearly reduced by conventional hormone replacement therapy. In this study, an estrogenic effect was also observed under CR BNO 1055. The MRS item 10 "joint and muscle symptoms", individually evaluated, was significantly improved by both, CE and CR BNO 1055, indicating estrogenic activities of CR BNO 1055.

    The data concerning bone metabolism deserve some detailed discussion. It is known that osteoblasts and osteoclasts are estrogen-receptive. In ovary-intact or estrogen-substituted women, the activity of osteoblasts and osteoclasts is well balanced, i.e. bone resorption initiated by osteoclasts is immediately counteracted by bone formation initiated by osteoblasts. Withdrawal of estrogen, in animal experiments, results in increased activities of both, osteoblasts and osteoclasts, i.e. an increased bone turnover [33]. Though both parameters were stimulated, the activity of osteoclasts was outbalanced, which lead to constant reduction of bone. This catabolic effect is counteracted by estrogens. Patients treated with C. racemosa BNO 1055 showed significantly increased serum levels of bone-specific alkaline phosphatase, which is indicative for an effect of osteoblast activity. This effect was not seen under treatment with CE. Patients treated with CE had decreased levels of serum CrossLaps, the metabolic products of bone-specific collagen-11. Low CrossLaps levels are the indication for a decreased activity of osteoclasts. As a net effect, in bones, the results for CR BNO 1055 and CE are comparable. The ratio of the bone-specific alkaline phosphatase:CrossLaps is significantly increased under both treatments, in comparison to placebo. Although the mechanism of action may be different from that of CE, which decrease osteoclast activity, CR BNO 1055 appears to have osteoprotective effects in bones by increasing osteoblast activity.

    It is suggested that not yet identified substances in the CR extract BNO 1055 bind to a yet unknown estrogen-binding site in the endometrium. Also, yet unknown dopaminergic compounds may contribute to the pharmacological profile of CR extract BNO 1055.



    à íàñêîëüêî ýòî áóäåò êëèíè÷åñêè ïðèåìëåìî, ïîêàæóò òåêóùèå êëèí. èññëåäîâàíèÿ:



    Nutr Clin Care 2002 Nov-Dec;5(6):283-9

    Black cohosh: an alternative therapy for menopause?

    Mahady GB, Fabricant D, Chadwick LR, Dietz B.

    UIC/NIH Center for Botanical Dietary Supplements Research, Program for Collaborative Research in the Pharmaceutical Sciences, University of Illinois, Chicago, Illinois, USA.

    Due to the long-term health risks now associated with hormone replacement therapy, many menopausal women are actively seeking alternative treatments. One such alternative is black cohosh (Actaea racemosa, syn. Cimicifuga racemosa), which has been used in the United States for the treatment of gynecologic complaints for more than 100 years. Review of the published clinical data suggests that black cohosh may be useful for the treatment of menopausal symptoms, such as hot flashes, profuse sweating, insomnia, and anxiety. Results from the most recently published trial, however, indicate that black cohosh is not effective for the treatment of menopausal symptoms in breast cancer survivors being treated with tamoxifen. Because the overall quality of the published clinical trials is low, two new randomized, double-blind, placebo-controlled clinical trials are currently underway in the United States. To date, only one standardized black cohosh extract has been tested clinically; the current recommended dose is 40-80 mg per day. At least 4-12 weeks of treatment may be required before any therapeutic benefits may be apparent. Adverse reactions such as nausea, vomiting, headaches, dizziness, mastalgia, and weight gain have been observed in clinical trials. No drug interactions are reported in the medical literature. The estrogenic effects of black cohosh are controversial, and the more recent data indicate that black cohosh extracts may have an anti-estrogenic activity. Owing to potential effects on sex hormones, however, black cohosh should not be administered to children or during pregnancy and lactation.

  10. Ghost
    #10
    ×èòàòåëü Íåäóã.Ðó
    ýäðàâñòâóéòå!

    ÿ - ñòóäåíòêà áèîôàêà êàëèíèíãðàäñêîãî ÃÓ è ïëàíèðóþ çàíèìàòüñÿ âëèÿíèåì ôèòîýñòðîãåíîâ íà ïîâåäåíèå ìîëëþñêîâ. à ñåé÷àñ âîò îáíàðóæèëà Âàøè êîììåíòàðèè ê òåìå î ôèòîýñòðîãåíàõ â ôîðóìå, íî, óâû, äâóõëåòíåé äàâíîñòè. åñëè ó Âàñ åñòü ññûëêè ïî ýòîé òåìå è ýòî íå î÷åíü Âàñ çàòðóäíèò, ÿ áóäó ÁÅÇÓÌÍÎ ðàäà! çàðàíåå áëàãîäàðþ )))

Êëèíèêà ñòîìàòîëîãèè è êîñìåòîëîãèè â Ìîñêâå

Ìåòêè ýòîé òåìû

Âàøè ïðàâà

  • Âû ìîæåòå ñîçäàâàòü íîâûå òåìû
  • Âû ìîæåòå îòâå÷àòü â òåìàõ
  • Âû íå ìîæåòå ïðèêðåïëÿòü âëîæåíèÿ
  • Âû íå ìîæåòå ðåäàêòèðîâàòü ñâîè ñîîáùåíèÿ
  •